S545-119

What This Bill Does

The Combating Illicit Xylazine Act treats xylazine as a controlled-substance problem without cutting off lawful veterinary uses. It defines xylazine, adds any material or mixture containing xylazine to schedule III unless excepted or listed elsewhere, rewrites the ultimate-user definition so animal owners, veterinarians, pharmacies, government animal-control programs, and wildlife programs can possess properly dispensed xylazine, delays labeling, packaging, logistics, practitioner-registration, inventory, and recordkeeping requirements, exempts existing manufacturers from new schedule III capital security expenditures, adds xylazine to ARCOS reporting, directs the Sentencing Commission to review penalties, and requires DEA/FDA coordination and congressional reporting.

Who Benefits and How

Veterinarians benefit because the bill preserves lawful dispensing and animal-use possession rather than treating ordinary veterinary xylazine as illicit possession. Animal owners, animal-control programs, and wildlife programs benefit from explicit ultimate-user language for animals under their care. DEA diversion investigators benefit from schedule III status and ARCOS tracking for xylazine movement. Communities affected by fentanyl-xylazine mixtures benefit if scheduling and sentencing updates reduce illicit trafficking. Existing xylazine manufacturers benefit from delayed compliance and an exemption from capital expenditures for schedule III manufacturing security standards.

Who Bears the Burden and How

Illicit xylazine traffickers face schedule III enforcement exposure and possible sentencing guideline changes. Veterinary pharmacies and practitioners must adapt to registration, inventory, recordkeeping, labeling, and distribution requirements as phase-in periods expire. DEA and FDA must expedite manufacturer submissions and coordinate implementation of xylazine scheduling. The Sentencing Commission must review and potentially amend guidelines for xylazine offenses. Congress and federal agencies must review reports on xylazine diversion, enforcement, and lawful animal-use access.

Key Provisions

• Adds xylazine and its salts and isomers to schedule III unless specifically excepted or listed elsewhere.
• Provides an animal-use ultimate-user rule for veterinarians, veterinary pharmacies, animal owners, government animal-control programs, and wildlife programs.
• Provides delayed phase-in periods for schedule III labeling, packaging, logistics, practitioner-registration, inventory, and recordkeeping requirements.
• Limits new capital security obligations by exempting existing xylazine manufacturers from schedule III manufacturing-security expenditures.
• Expands ARCOS tracking to xylazine and directs Sentencing Commission review and federal reporting.